Targeting human ovarian cancer with immune cells derived from the patient or from homozygous hla haplotype ips cells

Chimeric antigen receptors (CARs) have been used for efficient destruction of B cell tumors but have been relatively ineffective as therapy for solid tumors. Ovarian cancer is a difficult cancer to treat, with five-year survival rates commonly around 25% of patients at diagnosis.
Abstract (pdf)

Off-the-shelf iPSC derived CAR-NK immunotherapy for solid tumors

Principal Scientist Dr Nicholas Boyd

The clinical impact of Chimeric Antigen Receptor T cell (CAR-T) technologies on hematological malignancies have revolutionized cancer treatment. 

However, current autologous CAR-T therapies face major roadblocks for mass adoption. 

Published (pdf)
Abstract (pdf)

iScience Review – Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent Stem Cells

Despite progress in developing cell therapies, such as T cell or stemcell therapies to treat diseases, immunoincompatibility remains a major barrier to clinical application.

Given the fact that a host’s immune system may reject allogeneic transplanted cells, methods have been developed to genetically modify patients’primary cells.

Download (pdf)

Presentation: Cartherics on the Mesa

In October 2019 Cartherics attended the prestigious Cell & Gene Meeting on the Mesa https://www.meetingonthemesa.com/ in Carlsbad, California.

Cartherics Chief Scientific Officer, Richard Boyd, presented details to delegates of Cartherics’ pre-clinical in vitro and animal model research, cell manufacture for clinical trials, and corporate game plan.

Download (pdf)